Brimonidine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Brimonidine Availability in 2026

As an ophthalmologist, optometrist, or primary care provider who prescribes glaucoma medications, you've likely fielded calls from patients unable to fill their Brimonidine prescriptions. This briefing provides an evidence-based overview of the current supply situation, prescribing considerations, and practical tools to help your patients maintain uninterrupted therapy.

Current Status: Is There a Brimonidine Shortage?

As of Q1 2026, Brimonidine tartrate is not listed on the FDA's drug shortage database. Multiple generic manufacturers — including Apotex, Sandoz, and others — continue to produce brimonidine ophthalmic solution 0.2%. Brand-name Alphagan P (0.1% and 0.15%) also remains available through AbbVie/Allergan.

The patient-reported difficulty in finding Brimonidine is primarily driven by pharmacy-level inventory management rather than upstream manufacturing shortfalls. Contributing factors include:

• Algorithm-driven stocking at chain pharmacies that deprioritizes lower-volume ophthalmic products
• Formulation-specific stock-outs (e.g., 0.15% unavailable while 0.2% is in stock)
• Regional distribution variability, particularly in rural markets
• Intermittent production pauses at individual generic facilities that affect local supply without triggering national shortage classification

Timeline and Supply Context

Brimonidine has not experienced a major documented shortage comparable to drugs like Adderall or Ozempic. However, the broader ophthalmic drug supply chain has faced intermittent disruptions:

• 2022-2023: FDA-reported shortages of several ophthalmic products including certain artificial tears and antibiotic drops, driven by sterile manufacturing facility inspections
• 2024: Sporadic reports of brimonidine generic back-orders at specific distributors, resolved within weeks
• 2025-2026: Supply has stabilized, with no active FDA shortage listings for brimonidine formulations

The sterile manufacturing requirements for ophthalmic products remain a systemic vulnerability. Facilities producing eye drops must meet stringent cGMP standards, and quality-related shutdowns at any single facility can create temporary ripple effects across the market.

Prescribing Implications

When patients report difficulty filling Brimonidine, consider the following clinical strategies:

Formulation Flexibility

If a patient can't find their prescribed strength, consider whether a switch is clinically appropriate:

• Brimonidine 0.2% (generic) — most widely available and least expensive; the original formulation
• Brimonidine 0.15% (Alphagan P) — equivalent IOP-lowering efficacy to 0.2% with improved tolerability due to the Purite preservative
• Brimonidine 0.1% (Alphagan P) — slightly lower concentration with comparable efficacy in clinical trials

The 0.2% generic is typically the most findable option. For patients experiencing allergic conjunctivitis with the 0.2% formulation, switching to the Purite-preserved 0.15% Alphagan P — rather than discontinuing brimonidine entirely — may resolve tolerability issues while maintaining IOP control.

Therapeutic Alternatives

When Brimonidine is genuinely unavailable or poorly tolerated, evidence-based alternatives include:

• Latanoprost 0.005% (Xalatan) — prostaglandin analog, first-line per AAO Preferred Practice Pattern, once-daily dosing, IOP reduction of 25-35%
• Timolol 0.5% (Timoptic) — beta-blocker, once or twice daily, well-established efficacy. Contraindicated in asthma/COPD/bradycardia
• Dorzolamide 2% (Trusopt) — carbonic anhydrase inhibitor, three times daily. Available in combination with timolol (Cosopt)
• Apraclonidine 0.5% (Iopidine) — same drug class as Brimonidine. Useful as short-term bridge; tachyphylaxis limits long-term use

For comprehensive patient-facing information on alternatives, see our guide on alternatives to Brimonidine.

Availability and Access Picture

Helping patients locate Brimonidine often requires going beyond writing the prescription. Practical steps include:

• Directing patients to Medfinder for Providers — a real-time pharmacy inventory tool that shows which local pharmacies have Brimonidine in stock
• Recommending independent pharmacies — these often source from multiple wholesalers and have more inventory flexibility
• Facilitating e-prescribing to in-stock pharmacies — using Medfinder data to direct prescriptions where the medication is available
• Considering mail-order pharmacy — particularly beneficial for 90-day supplies and patients in underserved areas

Cost and Access Considerations

Cost barriers can compound availability issues, particularly for uninsured or underinsured patients:

• Generic Brimonidine 0.2%: $8-$40 retail; $7-$15 with discount cards (GoodRx, SingleCare). This is the most cost-effective option
• Brand Alphagan P: $200-$270 retail. AbbVie's At Your Service co-pay program covers up to $2,160/year for commercially insured patients
• Uninsured patients: Allergan Patient Assistance Program provides Alphagan P at no cost to eligible patients (rxabbvie.com)
• Insurance coverage: Generic brimonidine 0.2% is Tier 1 on most formularies. Brand Alphagan P may require prior authorization or step therapy through generic first

When cost is a primary barrier, prescribing the generic 0.2% formulation — which is therapeutically equivalent and widely covered — is the most pragmatic approach. For patients who need Alphagan P specifically, assist with the co-pay program enrollment.

For more details to share with patients, see how to save money on Brimonidine.

Tools and Resources for Your Practice

Streamline how your practice handles Brimonidine availability issues:

• Medfinder for Providers — check real-time pharmacy stock before sending prescriptions. Reduces patient callbacks and fill failures
• FDA Drug Shortage Database — monitor for any new brimonidine shortage listings at accessdata.fda.gov
• ASHP Drug Shortage Resource Center — additional supply monitoring and clinical guidance
• AbbVie Patient Resources — savewithays.com (co-pay assistance) and rxabbvie.com (patient assistance program)

Looking Ahead

The glaucoma treatment landscape continues to evolve with sustained-release technologies (e.g., Durysta bimatoprost implant), MIGS procedures, and novel drug delivery systems that may reduce dependence on daily topical medications. However, brimonidine ophthalmic drops will remain a cornerstone of glaucoma management for the foreseeable future.

Proactive inventory monitoring and flexible prescribing — both in terms of formulation strength and therapeutic class — remain the best strategies for ensuring your patients maintain uninterrupted IOP control.

Final Thoughts

Brimonidine supply in 2026 is stable at the manufacturing level, but pharmacy-level availability gaps continue to affect patients. By leveraging real-time stock-checking tools, maintaining prescribing flexibility across formulations and therapeutic classes, and connecting patients with cost-assistance programs, you can minimize treatment disruptions.

For additional provider resources:

• How to help your patients find Brimonidine in stock
• How to help patients save money on Brimonidine
• Brimonidine drug interactions: what to avoid
• How Brimonidine works: mechanism of action